Approaches to Reduce Therapeutic Inertia in Diabetes Management
A team of researchers investigated the effect of interventions to overcome therapeutic inertia regarding glycemic control in patients with type 2 diabetes.
A team of researchers investigated the effect of interventions to overcome therapeutic inertia regarding glycemic control in patients with type 2 diabetes.
Review authors summarized preliminary research on COVID-19 and past research on SARS-CoV-1 regarding their relationship with endocrine dysfunction.
For COVID-19 patients without a previous diagnosis of diabetes, fasting blood glucose (FBG) ≥7.0 mmol/L is an independent predictor of 28-day mortality.
Hyperglycemia may worsen outcomes in COVID-19 due to a rapid inflammatory response and increased glycosylation of the ACE2 receptor.
Findings showed a higher incidence of hyperglycemic episodes in patients with diabetes and comorbid schizophrenia than in those without schizophrenia.
Children of obese women with gestational diabetes have increased risk for childhood obesity.
Maternal glycemia during pregnancy may influence childhood glucose and insulin resistance regardless of BMI and family history of diabetes.
A patient, aged 60 years, was admitted to the hospital to undergo renal transplant therapy. He had a history of type 2 diabetes for 15 years.
When creating outpatient diabetes management plan, the patient’s inpatient medication regimen should be considered but not necessarily replicated.
In 2012, the ADA and the EASD published a position statement on the management of hyperglycemia in patients with T2DM. In January, 2015, the ADA and EASD issued an update to the original 2012 statement.